Gene · 10892
Papers2,863
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,863
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unlocking comprehensive molecular design across all scenarios with large language model and unordered chemical language. | Chem Sci | 2024 | 39211505 | PubTator, text mining | PubMed |
| Blood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma. | Oncol Lett | 2024 | 39161329 | PubTator, text mining | PubMed |
| CARD14 signalosome formation is associated with its endosomal relocation and mTORC1-induced keratinocyte proliferation. | Biochem J | 2024 | 39145956 | PubTator, text mining | PubMed |
| Blood MALT1 reflects acute exacerbation risk and inflammation in elderly chronic obstructive pulmonary disease patients. | Biomark Med | 2024 | 39136445 | PubTator, text mining | PubMed |
Mucosa‑associated lymphoid tissue lymphoma translocation protein 1 inhibitor, MI‑2, attenuates non‑small cell lung cancer cell proliferation, migration and invasion, and promotes apoptosis by suppressing the JNK/c‑JUN pathway. | Oncol Lett | 2024 | 39119234 | PubTator, text mining | PubMed |
| An improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification. | Nat Commun | 2024 | 39103360 | PubTator, text mining | PubMed |
| B cells expressing mutated IGHV1-69-encoded antigen receptors related to virus neutralization show lymphoma-like transcriptomes in patients with chronic HCV infection. | Hepatol Commun | 2024 | 39082968 | PubTator, text mining | PubMed |
| PRRSV utilizes MALT1-regulated autophagy flux to switch virus spread and reserve. | Autophagy | 2024 | 39081059 | PubTator, text mining | PubMed |
| Changes in mucosa‑associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‑1 inhibitor monotherapy. | Oncol Lett | 2024 | 39049986 | PubTator, text mining | PubMed |
| A novel MALT1 variant in an Egyptian patient presenting with exfoliative dermatitis: a case-based review. | Immunol Res | 2024 | 39017781 | PubTator, text mining | PubMed |
| Insights into mechanisms of MALT1 allostery from NMR and AlphaFold dynamic analyses. | Commun Biol | 2024 | 39014105 | PubTator, text mining | PubMed |
| How nurses face a new era of genomics medicine and precision health: Oncology nurse clinicians' perspective. | Asia Pac J Oncol Nurs | 2024 | 39006319 | PubTator, text mining | PubMed |
| RNA editing landscape of adipose tissue in polycystic ovary syndrome provides insight into the obesity-related immune responses. | Front Endocrinol (Lausanne) | 2024 | 38978626 | PubTator, text mining | PubMed |
| The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar Diseases. | ACS Med Chem Lett | 2024 | 38894907 | PubTator, text mining | PubMed |
| The COP9 signalosome stabilized MALT1 promotes Non-Small Cell Lung Cancer progression through activation of NF-κB pathway. | Cell Biol Toxicol | 2024 | 38864940 | PubTator, text mining | PubMed |
| The Genetic Landscape of Primary Breast Marginal Zone Lymphoma Identifies a Mutational-driven Disease With Similarities to Ocular Adnexal Lymphoma. | Am J Surg Pathol | 2024 | 38864239 | PubTator, text mining | PubMed |
| MALT1 substrate cleavage: what is it good for? | Front Immunol | 2024 | 38863711 | PubTator, text mining | PubMed |
| Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death. | Blood Adv | 2024 | 38820414 | PubTator, text mining | PubMed |
| Polo-like kinase 1 (PLK1) is a novel CARD14-binding protein in keratinocytes. | Biochem Pharmacol | 2024 | 38797267 | PubTator, text mining | PubMed |
| Learning with filopodia and spines: Complementary strong and weak competition lead to specialized, graded, and protected receptive fields. | PLoS Comput Biol | 2024 | 38743789 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10892/papers?page=7